로딩 중…
지수 로딩 중…
Onconic Therapeutics
476060· KOSDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences
₩12,410+2.48%
2026-11-02
Financials
Valuation Metrics
Onconic Therapeutics's Market Cap is ₩5635B. At end of 2025 it was ₩8877B. Ranked #412 of 2,405 in KR market (top 17%), #143 of 1,627 on KOSDAQ (top 9%), #46 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 20%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 563.51B KRW | KR#412/2,405 Sec#46/231 |
| Revenue | 82.17B KRW | KR#1,533/2,405 Sec#97/231 |
| Net Income | 24.25B KRW | KR#634/2,405 Sec#39/231 |
| Total Assets | 75.71B KRW | KR#1,960/2,405 Sec#162/231 |
| Net Assets | 72.04B KRW | KR#1,666/2,405 Sec#140/231 |
| Employees | 38 | KR#2,135/2,405 Sec#198/231 |
| Value | ||
| P/E | 23.24x | KR#1,254/2,405 Sec#76/231 |
| P/B | 7.82x | KR#2,330/2,405 Sec#208/231 |
| P/S | 6.86x | KR#2,220/2,405 Sec#154/231 |
| EV/EBITDA | 29.85x | KR#1,214/2,405 Sec#76/231 |
| FCF Yield | 1.97% | KR#1,068/2,405 Sec#71/231 |
| Profitability | ||
| ROE | 33.66% | KR#44/2,405 Sec#4/231 |
| ROA | 32.03% | KR#16/2,405 Sec#3/231 |
| Op. Margin | 21.06% | KR#149/2,405 Sec#16/231 |
| Revenue Growth | 259.82% | KR#25/2,405 Sec#7/231 |
| Financial Health | ||
| Debt Ratio | 5.09% | KR#36/2,405 Sec#12/231 |
| Total Debt | 0 KRW | KR—/2,405 Sec—/231 |
| FCF | 11.09B KRW | KR#689/2,405 Sec#39/231 |
| Cash | 47.05B KRW | KR#769/2,405 Sec#46/231 |
| Net Debt/EBITDA | -2.72x | KR#182/2,405 Sec#8/231 |
| Performance | ||
| 1Y Return | -27.60% | KR#1,060/2,405 Sec#67/231 |
| 1M Return | -21.01% | KR#1,926/2,405 Sec#190/231 |
| From 52W High | -57.06% | KR#1,508/2,405 Sec#121/231 |
| 1Y MDD | -63.84% | KR#1,661/2,405 Sec#137/231 |
| Trading | ||
| Volume | 96,040 shares | KR#647/2,405 Sec#67/231 |
| Trading Value | 1.17B KRW | KR#547/2,405 Sec#55/231 |
| Foreign Own. | 0.02% | KR#2,270/2,405 Sec#219/231 |
| Per Share | ||
| EPS | 534 KRW | KR#970/2,405 Sec#68/231 |
| BPS | 1,586 KRW | KR#2,173/2,405 Sec#187/231 |
Company Info
Onconic Therapeutics, Inc. operates as a biopharmaceutical enterprise, primarily dedicated to the discovery and advancement of novel therapeutic solutions. Its research and development initiatives principally focus on creating new medications for acid-related ailments and various oncological conditions. This company was established on May 7, 2020, and maintains its principal office in Seoul, South Korea.